Caitlyn Stulpin on Muck Rack

Caitlyn Stulpin

Verified
  • Staff Writer, SLACK Incorporated, Healio
New Jersey
As seen in: Healio, NJ.com, Suburban News, The Star-Ledger, The Times-Picayune | The New Orleans Advocate, EIN News, Healio Primary Care, Infectious Diseases News, The Intelligencer (Doylestown, PA), Burlington County Times, Citeline
🦠Infectious disease reporter for @InfectDisNews 🥊Boxer/Boxing coach. Movie buff, stress baker & CrossFitter 🏋🏼‍♀️ Opinions are all me.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Caitlyn

Contact Caitlyn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Conference on Retroviruses and Opportunistic Infections (CROI)

|
By Caitlyn Stulpin 
| Infectious Diseases News
Key takeaways: Previous studies have shown that DOR/ISL was noninferior to continuing current HIV therapies At 48 weeks, 91.8% of people on DOR/ISL were virally suppressed vs. 90.6% on BIC/FTC/TAF. DENVER — A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according to phase 3 data shared at the Conference on Opportunistic Infections and Retroviruses.
Open in Who Shared Issue with article?

Conference on Retroviruses and Opportunistic Infections (CROI)

|
By Caitlyn Stulpin , Kristen Dowd 
| Citeline
Ask a clinical question and tap into Healio AI's knowledge base. Key takeaways: Previous studies have shown that DOR/ISL was noninferior to continuing current HIV therapies At 48 weeks, 91.8% of people on DOR/ISL were virally suppressed vs. 90.6% on BIC/FTC/TAF. DENVER — A novel regimen of doravirine and islatravir was noninferior to a common HIV therapy as an initial HIV treatment, according to phase 3 data shared at the Conference on Opportunistic Infections and Retroviruses.
Open in Who Shared Issue with article?

US less safe without permanent CDC director, experts warn

|
By Anthony Stitt , Caitlyn Stulpin , Sara Kellner 
| Infectious Diseases News
Loading the Elevenlabs Text to Speech AudioNative Player... Key takeaways: The CDC has not had a permanent director for 13 of the last 14 months. The vacancy leaves the U.S. open to public health threats, experts said. NIH Director Jay Bhattacharya, MD, PhD, was selected in February to also serve as acting director of the CDC, continuing the unprecedented turnover atop what is widely considered to be the world’s premier public health agency.
Open in Who Shared Issue with article?
See all 2,419 articles

Actions

Share this page

Get in touch with Caitlyn

Contact Caitlyn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified